Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$6.70 USD
-0.34 (-4.83%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $6.65 -0.05 (-0.75%) 4:54 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MRSN 6.70 -0.34(-4.83%)
Will MRSN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRSN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRSN
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
MRSN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Other News for MRSN
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 | MRSN ...
Mersana Therapeutics trading halted, news pending
MRSN Trading Halted Due to Pending News
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split | MRSN Stock News
Mersana Therapeutics (MRSN) Implements 1-for-25 Reverse Stock Split | MRSN Stock News